Interpace Biosciences, Inc. (IDXG) Fair Value 2026

IDXG · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.2 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-08-27, Interpace Biosciences, Inc. (IDXG) trades at $1.45, versus a $3.51 median fair value across its 9 active models — 141.9% above the current price. QOC: 8.2/10. Value Trap Risk: 24/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $4.52.

Key Facts

Ticker
IDXG
Price
$1.45
Quality Score
8.2/10
Value Trap Risk
24/100
Models Active
9/13
Last Updated
Strength: Bayesian DCF suggests +211.4% upside with 66% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Is Interpace Biosciences, Inc. (IDXG) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Interpace Biosciences, Inc. (IDXG) appears undervalued as of : the median of 9 independent fair value estimates is $3.51, 141.9% above the current price of $1.45. Estimates range from $0.32 to $5.76. IDXG scores 8.2/10 on fundamental quality and 24/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. IDXG’s +141.9% gap is wider than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Interpace Biosciences, Inc. Stock in 2026? →

What Fair Value Does Each Model Give IDXG?

9 Intrinsic Value Models vs. Current Price ($1.45)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $4.52 +211.4%
Ensemble · Low Conviction
 $3.46 +138.8%
Intrinsic · High Conviction
 $4.51 +211.2%
Asset-Based · High Conviction
 $0.32 -77.9%
Unlock the Full Matrix

Access 5 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is IDXG's Fair Value Range?

Spread across 9 independent models · $0.32 to $5.76

CirclFi's 9 active models place Interpace Biosciences, Inc. (IDXG) between $0.32 and $5.76 per share, a spread of 155% of the median. The median of that range — $3.51 — is the fair value CirclFi publishes for IDXG, against a current price of $1.45.

Low · Dynamic NAVHigh · FTNN
$0.32median $3.51$5.76
Where the range comes from
Most bearish modelDynamic NAV$0.32
Most bullish modelFTNN Topology$5.76
Model agreement7 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for IDXG. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on IDXG, not a CirclFi price target. How each model works →

What Is Interpace Biosciences, Inc. (IDXG) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Interpace Biosciences, Inc.. Trading at $1.45 against an estimated intrinsic value of $3.51, 7 of 9 active models flag meaningful upside of +141.9% at the median. The most optimistic model, FTNN, places fair value at $5.76 (+297.5%), while Dynamic NAV — the most conservative — estimates $0.32 (-77.9%). This +375.3% gap reflects genuine analytical uncertainty about Interpace Biosciences, Inc.'s intrinsic worth.

What Do the Models Say About IDXG?

9 of 13 models are currently active for IDXG. Of these, 7 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for IDXG is $3.51 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $4.52 on its own, implying +211.4% upside from the current price. See which stocks rank higher →

How Does IDXG Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, IDXG ranks #8 by Quality of Company score. CirclFi's QOC score of 8.2/10 evaluates 32 fundamental signals. A score of 8.2 places IDXG in the top tier.

The Diagnostics & Research sector introduces analytical considerations specific to pharmaceutical industry businesses. For Interpace Biosciences, Inc., metrics like revenue per drug provide important context that general-purpose valuation models may underweight.

Is IDXG a Value Trap?

CirclFi's Value Trap algorithm assigns IDXG a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Interpace Biosciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Interpace Biosciences, Inc. scores 8.2 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +375.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IDXG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IDXG's 9 active models, average confidence is 41%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Interpace Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

IQVIQVIA Holdings Inc.QOC 8.3DHRDanaher CorporationQOC 8.1MTDMettler-Toledo International Inc.QOC 8.7SHCSotera Health CompanyQOC 8.1ILMNIllumina, Inc.QOC 8.8DGXQuest Diagnostics IncorporatedQOC 7.9CDNACareDx, Inc.QOC 7.3AWHLAspira Women's Health Inc.QOC 6.4NDRAENDRA Life Sciences Inc.QOC 4.0IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: IQV · DHR · MTD · SHC · ILMN · DGX · CDNA · AWHL · NDRA · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to IDXG?

7 companies across all industries closest to IDXG’s Quality of Company score of 8.2/10.

PNCThe PNC Financial Services Group, Inc.QOC 8.2CNACNA Financial CorporationQOC 8.2PLDPrologis, Inc.QOC 8.2EPAMEPAM Systems, Inc.QOC 8.2VALValaris LimitedQOC 8.2FBRTFranklin BSP Realty Trust, Inc.QOC 8.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PNC · CNA · PLD · EPAM · VAL · FBRT · NVDA

What Else Do Investors Ask About Interpace Biosciences, Inc.’s Valuation?

What is Interpace Biosciences, Inc.'s intrinsic value in 2026?

CirclFi puts Interpace Biosciences, Inc. (IDXG)'s intrinsic value at $3.51 — the median of 9 independent model estimates as of 2026-08-27, ranging from $0.32 to $5.76. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $4.52 on its own. The Quality of Company score is 8.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IDXG overvalued or undervalued right now?

At $1.45, 7 of 9 active models suggest IDXG may be undervalued, while 2 indicate potential overvaluation. The median of all 9 fair value estimates is $3.51, 141.9% above the current price of $1.45 — a consensus view that IDXG is undervalued. The assessment depends on which methodology best fits Interpace Biosciences, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 8.2 mean for IDXG?

Interpace Biosciences, Inc.'s QOC of 8.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on IDXG?

CirclFi analyzes IDXG with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on IDXG?

Of the 9 models currently active on IDXG, FTNN Topology is the most bullish at $5.76 per share, and Dynamic NAV is the most bearish at $0.32. CirclFi's published fair value for IDXG is the median of that range, $3.51, not either extreme. The gap between the two ends equals 155% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is IDXG a value trap in 2026?

Interpace Biosciences, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Interpace Biosciences, Inc. (IDXG) has a median fair value of $3.51 — 141.9% above the current price of $1.45 — as of 2026-08-27.” Source: circlfi.com/stock/IDXG/ · Methodology
Primary sources for this IDXG valuation
  • Financial statements: Interpace Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001054102) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for IDXG as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on IDXG.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for IDXG Unlock All 9 — $39/mo